drugset / Trial / NCT06663332

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332

Phase 3 Recruiting 196 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

Timeline

Start
2024-10-29
Primary completion
2031-12-12
Completion
2032-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Subcutaneous